Would you give one breath if you could detect lung cancer and other diseases?
Introducing OneBreath™
A unique technology platform developed by Breath Diagnostics to quantitatively analyze organic compounds in a single breath to detect lung cancer and other diseases.1
Our highly portable system will be readily available to patients through medical providers.1
In contrast to a Low-Dose CT Scan, OneBreath is a quicker and easier way of lung cancer diagnosis. We are currently enrolling patients for our 2nd generation system Pilot Study.
Breath Collection
Patients provide one complete breath via a unique collection system in less than 30 seconds.
Breath Processing and Analysis
In a simple automated process, the OneBreath™ micro-reactor captures the organic compounds contained in the breath. Once captured, the samples is analyzed in our laboratories.
Get Results
Results will be available within 3-4 business days.
Why OneBreath™?
OneBreath™ provides a safe, convenient, and inexpensive way to identify lung cancer in at risk patients, before they know they have a problem.1
Accurate Results
OneBreath™ detects lung cancer with fewer false positives and higher specificity than a low-dose CT scan.
Accessible
The OneBreath™ system increases access to potentially life-saving lung cancer screenings by being portable enough for use in a physician's office or local pharmacy.
Affordable
The OneBreath™ technology platform demonstrates a lower false positive rate versus CT scans, reducing the number of unnecessary follow-up diagnostic procedures.
Easy to Use
The simplicity of the OneBreath™ system provides the potential to enhance screening compliance due to the fact that only a single breath is required.
Research & Publications
Detection of COVID-19 by quantitative analysis of carbonyl compounds in exhaled breath
UHPLC-MS in combination with a MEMS-fabricated silicon microreactor was used to analyze carbonyl compounds in exhaled breath to differentiate COVID-19 positive and negative subjects. The sensitivity increased when modeling variants separately. The overall results are promising for SARS-CoV-2 detection. When all positive (both Alpha and Delta) and all negative samples were used for training a logistic regression algorithm, the model still achieved 90.1% sensitivity, 98.3% specificity and 94.7% accuracy.
Research
June 24, 2024
Analysis of a Broad Range of Carbonyl Metabolites in Exhaled Breath by UHPLC-MS
The combination of a silicon microreactor for the selective capture of carbonyl compounds with UHPLC-MS analysis may provide a quantitative method for the analysis of carbonyls to identify disease markers in exhaled breath.
Research
February 23, 2024
Testimonials
To the promise of breath based lung cancer diagnostics and what Breath diagnostics could offer patients
"Technology like OneBreath has so much potential for improving and saving lives."
Dr. Kevin Gardner
Executive VP Research and Innovation, University of Louisville
OneBreath™ by Breath Diagnostics
OneBreath™ may save your life.
Contact us to discover the future of lung cancer screening or click below to learn more.1
